Economic burden of cervical cancer in Malaysia

Medical Journal of Indonesia

Volumn 17, Issue 4, 2008, Pages 272-280

  Puteh, Sharifa Ezat Wan ^a   Ng, Paul ^a   Aljunid, Syed Mohamed ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b United Nations University   (Malaysia)

Author keywords

Cervical cancers; HPV vaccination; Pre invasive disease

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CONSENSUS; COST BENEFIT ANALYSIS; COST OF ILLNESS; CYSTOSCOPY; DRUG COST; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; MALAYSIA; PAPANICOLAOU TEST; POST TREATMENT SURVIVAL; PUNCH BIOPSY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; SURVIVAL RATE; TUMOR INVASION; UTERINE CERVIX CANCER; VACCINATION; VISCERAL METASTASIS;

EID: 85008940798     PISSN: 08531773     EISSN: 22528083     Source Type: Journal    
DOI: 10.13181/mji.v17i4.330     Document Type: Article

References (16)

1. Goldie SJ, Kohli M, Grima D, Weintein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute. 2004; 96:604-15.
2. National Cancer Registry. Second report of the national cancer registry cancer incidence in Malaysia. 2003.
3. Guidebook for Pap smear screening. Division of Family Health Development. Ministry of Health Malaysia. 2004.
4. Clinical Practice Guideline: Management of Cervical cancers. Ministry of Health Malaysia. 2003.
5. Morantz CA. ACOG releases guidelines for management of abnormal cervical cytology and histology. Am Fam Physician. 2006;73:719-23.
6. Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Nat Cancer Instit. 2002;94:1469-83.
7. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter L, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England J Med. 2007;356:1928-43.
8. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine; recommendations of the Advisory Committee on Immunization Practices. 2007: 56(RR-2):1-24.
9. Ibrahim NSM. Effectiveness of Pap smears Screening in the Detection of Cervical Cancer [Thesis]. Kuala Lumpur. Universiti Kebangsaan Malaysia. 2005.
10. Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of Cervical cancer, cervical dysplasia and genital warts in the UK. Current Med Research and Options. 2006;22:663-70.
11. Balasubramani L, Tidy J. Hope for cervical cancer screening. Hospital Doctor. 2006.
12. Kim JJ, Thomas CW, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France and Italy. J Nat Cancer Instit. 2005; 97: 888–95.
13. Wong C, Visram F, Cook D, Griffith L, Randall J, O’Brien B, et al. Development, dissemination, implementation and evaluation of a clinical pathway for oxygen therapy. Canadian Medical Association Journal. 2000; 162:29-33.
14. Panella M, Marchisio S, Stanislao F. Reducing clinical variations with clinical pathways: do pathways work? Intl J Quality in Health Care. 2003; 15:509-21.
15. Loeb M, Carusone SC, Goeree R, Walter SD, Brazil K, Krueger P, et al. Effects of a clinical pathway to reduce hospitalizations in nursing home residents with penumonia. J Am Med Assoc. 2006;295:2503-10.
16. FIGO Committee on Gynaecologic Oncology. Staging classifications and clinical practice guidelines for gynaecologic cancers. Intl J Gynaecol Obstet. 2000;70:207-312.